Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; P… Read more
Market Cap & Net Worth: Nektar Therapeutics (NKTR)
Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $1.53 Billion ($1.53 Billion) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6024 globally and #3455 in its home market, demonstrating a 8.54% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nektar Therapeutics's stock price $75.06 by its total outstanding shares 20341589 (20.34 Million).
Nektar Therapeutics Market Cap History: 2015 to 2026
Nektar Therapeutics's market capitalization history from 2015 to 2026. Data shows growth from $342.76 Million to $1.53 Billion (19.94% CAGR).
Index Memberships
Nektar Therapeutics is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.06% | #174 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #712 of 3165 |
Weight: Nektar Therapeutics's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nektar Therapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nektar Therapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.19x
Nektar Therapeutics's market cap is 0.19 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $342.76 Million | $230.78 Million | -$81.18 Million | 1.49x | N/A |
| 2016 | $249.59 Million | $165.44 Million | -$153.52 Million | 1.51x | N/A |
| 2017 | $1.21 Billion | $307.71 Million | -$96.69 Million | 3.95x | N/A |
| 2018 | $668.63 Million | $1.19 Billion | $681.31 Million | 0.56x | 0.98x |
| 2019 | $439.07 Million | $114.62 Million | -$440.67 Million | 3.83x | N/A |
| 2020 | $345.81 Million | $152.91 Million | -$444.44 Million | 2.26x | N/A |
| 2021 | $274.81 Million | $101.91 Million | -$523.84 Million | 2.70x | N/A |
| 2022 | $45.97 Million | $92.06 Million | -$368.20 Million | 0.50x | N/A |
| 2023 | $11.49 Million | $90.12 Million | -$276.06 Million | 0.13x | N/A |
| 2024 | $18.92 Million | $98.43 Million | -$118.96 Million | 0.19x | N/A |
Competitor Companies of NKTR by Market Capitalization
Companies near Nektar Therapeutics in the global market cap rankings as of March 19, 2026.
Key companies related to Nektar Therapeutics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Nektar Therapeutics Historical Marketcap From 2015 to 2026
Between 2015 and today, Nektar Therapeutics's market cap moved from $342.76 Million to $ 1.53 Billion, with a yearly change of 19.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.53 Billion | +77.52% |
| 2025 | $860.04 Million | +4446.24% |
| 2024 | $18.92 Million | +64.60% |
| 2023 | $11.49 Million | -75.00% |
| 2022 | $45.97 Million | -83.27% |
| 2021 | $274.81 Million | -20.53% |
| 2020 | $345.81 Million | -21.24% |
| 2019 | $439.07 Million | -34.33% |
| 2018 | $668.63 Million | -44.96% |
| 2017 | $1.21 Billion | +386.72% |
| 2016 | $249.59 Million | -27.18% |
| 2015 | $342.76 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Nektar Therapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.53 Billion USD |
| MoneyControl | $1.53 Billion USD |
| MarketWatch | $1.53 Billion USD |
| marketcap.company | $1.53 Billion USD |
| Reuters | $1.53 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.